Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Multiple Myeloma × Ibandronic Acid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasm Metastasis 12 Pain 10 Bone Neoplasms 8 Breast Neoplasms 6 Humoral Hypercalcemia Of Malignancy 2 Prostatic Neoplasms 1 Osteoporosis 1 Multiple Myeloma 1 Lung Neoplasms 1 Hematologic Neoplasms 1 Esophageal Neoplasms 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma, Squamous Cell 1 Carcinoma, Renal Cell 1 Breast Neoplasms, Male 1 Bone Diseases, Metabolic 1 Adenocarcinoma 1

Interventions

Dexamethasone 672 Bortezomib 378 Lenalidomide 361 Cyclophosphamide 288 Melphalan 218 Calcium Dobesilate 196 daratumumab 184 pomalidomide 161 carfilzomib 145 Thalidomide 103 fludarabine 100 fludarabine phosphate 96 Peripheral Blood Stem Cell Transplantation 95 Filgrastim 95 ixazomib 74 Granulocyte Colony-Stimulating Factor 69 Whole-Body Irradiation 68 dexamethasone acetate 66 Mycophenolic Acid 65 Busulfan 65 Tacrolimus 58 dexamethasone 21-phosphate 56 Prednisone 55 Cyclosporine 53 auricularum 52 isatuximab 51 elotuzumab 50 belantamab mafodotin 49 Antilymphocyte Serum 46 Etoposide 44

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02739594 2016-07-22

COMPARE

Hoffmann-La Roche

Phase 3 Terminated

89 enrolled 17 charts

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡